LVCLY

Living Cell Technologies (QX) Share Price - LVCLY

0.10
0.02 (25.0%)
0.10
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Living Cell Technologies Ltd (QX) LVCLY OTCMarkets Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.02 25.0% 0.10 0.10 0.10 0.10 0.08 09:30:01
Bid Price Ask Price Spread Spread % News
0.10 0.15 0.05 33.33% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
1 520  0.10  52 1,054
Last Trade Time Type Quantity Stock Price Currency
09:30:01 520  0.10 USD

Living Cell Technologies (QX) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 57.14M 571.44M -  -  - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
6.08k  - 0.00% - -

more financials information »

News Living Cell Technologies (QX)

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

LVCLY Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercializing regenerative treatments which restore function using naturally occurring cells. LCT's lead product NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases. LCT's proprietary encapsulation technology, IMMUPEL, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes. LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.


Your Recent History
USOTC
LVCLY
Living Cel..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.